Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years. The total duration of the study is therefore of 7 years.

Trial Details

NCT ID
NCT07254754
Phase
PHASE2
Sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Axicabtagene Ciloleucel
Locations (sample)
  • A Coruña, A Coruña, Spain|43.37135,-8.396
  • Palma de Mallorca, Balearic Islands, Spain|39.56939,2.65024
  • Santander, Cantabria, Spain|43.46589,-3.80493
  • Salamanca, Castille and León, Spain|40.96882,-5.66388
  • Barcelona, Catalonia, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Signed written Informed Consent Form
  • Age \> 18 years
  • Patient who understands and speaks one of the country official languages
  • Histologically proven relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL) of the following histology at relapse: diffuse large B-…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →